Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00121641




Registration number
NCT00121641
Ethics application status
Date submitted
15/07/2005
Date registered
21/07/2005
Date last updated
3/04/2015

Titles & IDs
Public title
Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
Scientific title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise
Secondary ID [1] 0 0
CV181-011
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 2 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Saxagliptin
Treatment: Drugs - Saxagliptin
Treatment: Drugs - Saxagliptin
Treatment: Drugs - Placebo matching Saxagliptin
Treatment: Drugs - Metformin
Treatment: Drugs - Placebo matching Metformin
Treatment: Drugs - Saxagliptin
Treatment: Drugs - Metformin

Experimental: Saxagliptin 2.5 mg (A) - Metformin 500-2000 mg (as needed for rescue)

Experimental: Saxagliptin 5 mg (B) - Metformin 500-2000 mg (as needed for rescue)

Experimental: Saxagliptin 10 mg (C) - Metformin 500-2000 mg (as needed for rescue)

Placebo Comparator: Placebo (D) - Metformin 500-2000 mg (as needed for rescue)

Experimental: Open-Label Treatment Cohort (Direct Enrollees) (E) - Saxagliptin 10 mg
Metformin 500-2000 mg (as needed for rescue)


Treatment: Drugs: Saxagliptin
Tablets, Oral, 2.5 mg, Once daily (24 weeks short term [ST], 42 months long term [LT])

Treatment: Drugs: Saxagliptin
Tablets, Oral, 5 mg, Once daily (24 weeks ST, 42 months LT)

Treatment: Drugs: Saxagliptin
Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT)

Treatment: Drugs: Placebo matching Saxagliptin
Tablets, Oral, 0mg, Once daily (24 weeks ST, 42 months LT)

Treatment: Drugs: Metformin
Tablets, Oral, 500 mg, daily (42 months LT)

Treatment: Drugs: Placebo matching Metformin
Tablets, Oral, 0 mg, daily (42 months LT)

Treatment: Drugs: Saxagliptin
Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT) Open Label

Treatment: Drugs: Metformin
Tablets, Oral, 500-2000 mg (as needed for rescue)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Hemoglobin A1c (A1C) Changes From Baseline at Week 24
Timepoint [1] 0 0
Baseline, Week 24
Primary outcome [2] 0 0
A1C Changes From Baseline at Week 24 - Open Label Cohort
Timepoint [2] 0 0
Baseline, Week 24
Secondary outcome [1] 0 0
Baseline and Change From Baseline at Week 24 in Fasting Plasma Glucose (FPG)
Timepoint [1] 0 0
Baseline, Week 24
Secondary outcome [2] 0 0
Percentage of Participants Achieving Therapeutic Glycemic Response (A1C < 7.0%) at Week 24
Timepoint [2] 0 0
Week 24
Secondary outcome [3] 0 0
Baseline and Change From Baseline at Week 24 in Postprandial Glucose (PPG) Area Under the Curve (AUC)
Timepoint [3] 0 0
Baseline, Week 24
Secondary outcome [4] 0 0
Baseline and Change From Baseline at Week 24 in Fasting Plasma Glucose (FPG) - Open Label Cohort
Timepoint [4] 0 0
Baseline, Week 24
Secondary outcome [5] 0 0
Percentage of Participants Achieving Therapeutic Glycemic Response (A1C < 7.0%) at Week 24 - Open Label Cohort
Timepoint [5] 0 0
Week 24
Secondary outcome [6] 0 0
Baseline and Change From Baseline at Week 24 in Postprandial Glucose (PPG) Area Under the Curve (AUC) - Open Label Cohort
Timepoint [6] 0 0
Baseline, Week 24

Eligibility
Key inclusion criteria
- Type 2 diabetes mellitus

- Drug naive

- Hemoglobin (Hb) A1c >= 7.0% and <= 10.0% (>10% and <= 12% for open label arm)

- Fasting C-peptide >= 1 ng/mL

- Body mass index <= 40 kg/m2
Minimum age
18 Years
Maximum age
77 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Symptomatic poorly controlled diabetes

- Recent cardiac or cerebrovascular event

- Serum creatinine >= 1.5 mg/dL for males and >= 1.4 mg/dL for Women of Child Bearing
Potential

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/07/2005
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2010
Sample size
Target
Accrual to date
Final
1035
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA
Recruitment hospital [1] 0 0
Local Institution - Sydney
Recruitment hospital [2] 0 0
Local Institution - Woollongong
Recruitment hospital [3] 0 0
Local Institution - Brisbane
Recruitment hospital [4] 0 0
Local Institution - Kippa Ring
Recruitment hospital [5] 0 0
Local Institution - Meadowbrook
Recruitment hospital [6] 0 0
Local Institution - Adelaide
Recruitment hospital [7] 0 0
Local Institution - Woodville South
Recruitment hospital [8] 0 0
Local Institution - Perth
Recruitment postcode(s) [1] 0 0
- Sydney
Recruitment postcode(s) [2] 0 0
- Woollongong
Recruitment postcode(s) [3] 0 0
- Brisbane
Recruitment postcode(s) [4] 0 0
- Kippa Ring
Recruitment postcode(s) [5] 0 0
- Meadowbrook
Recruitment postcode(s) [6] 0 0
- Adelaide
Recruitment postcode(s) [7] 0 0
- Woodville South
Recruitment postcode(s) [8] 0 0
- Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Mississippi
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
Montana
Country [17] 0 0
United States of America
State/province [17] 0 0
Nebraska
Country [18] 0 0
United States of America
State/province [18] 0 0
Nevada
Country [19] 0 0
United States of America
State/province [19] 0 0
New Jersey
Country [20] 0 0
United States of America
State/province [20] 0 0
New York
Country [21] 0 0
United States of America
State/province [21] 0 0
North Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Ohio
Country [23] 0 0
United States of America
State/province [23] 0 0
Oklahoma
Country [24] 0 0
United States of America
State/province [24] 0 0
Oregon
Country [25] 0 0
United States of America
State/province [25] 0 0
Pennsylvania
Country [26] 0 0
United States of America
State/province [26] 0 0
South Carolina
Country [27] 0 0
United States of America
State/province [27] 0 0
Tennessee
Country [28] 0 0
United States of America
State/province [28] 0 0
Texas
Country [29] 0 0
United States of America
State/province [29] 0 0
Utah
Country [30] 0 0
United States of America
State/province [30] 0 0
Virginia
Country [31] 0 0
United States of America
State/province [31] 0 0
Washington
Country [32] 0 0
Canada
State/province [32] 0 0
Alberta
Country [33] 0 0
Canada
State/province [33] 0 0
British Columbia
Country [34] 0 0
Canada
State/province [34] 0 0
Manitoba
Country [35] 0 0
Canada
State/province [35] 0 0
New Brunswick
Country [36] 0 0
Canada
State/province [36] 0 0
Newfoundland and Labrador
Country [37] 0 0
Canada
State/province [37] 0 0
Ontario
Country [38] 0 0
Canada
State/province [38] 0 0
Prince Edward Island
Country [39] 0 0
Canada
State/province [39] 0 0
Quebec
Country [40] 0 0
Canada
State/province [40] 0 0
Saskatchewan
Country [41] 0 0
Mexico
State/province [41] 0 0
Distrito Federal
Country [42] 0 0
Mexico
State/province [42] 0 0
Jalisco
Country [43] 0 0
Mexico
State/province [43] 0 0
Nuevo Leon
Country [44] 0 0
Mexico
State/province [44] 0 0
Sonora
Country [45] 0 0
Mexico
State/province [45] 0 0
Aguascalientes
Country [46] 0 0
Mexico
State/province [46] 0 0
Durango
Country [47] 0 0
Puerto Rico
State/province [47] 0 0
Carolina
Country [48] 0 0
Puerto Rico
State/province [48] 0 0
Guaynabo
Country [49] 0 0
Puerto Rico
State/province [49] 0 0
Ponce
Country [50] 0 0
Puerto Rico
State/province [50] 0 0
Rio Piedras
Country [51] 0 0
Puerto Rico
State/province [51] 0 0
San Juan
Country [52] 0 0
Taiwan
State/province [52] 0 0
Hualien
Country [53] 0 0
Taiwan
State/province [53] 0 0
Taichung
Country [54] 0 0
Taiwan
State/province [54] 0 0
Taipei

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is
more effective than placebo as a treatment for type 2 diabetic subjects who are not
sufficiently controlled with diet and exercise
Trial website
https://clinicaltrials.gov/ct2/show/NCT00121641
Trial related presentations / publications
Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R; CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009 Oct;25(10):2401-11. doi: 10.1185/03007990903178735.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00121641